Open AccessA Review on Antiviral Activity of Favipiravir
Author(s) -
Mariya Palathingal,
M. Archana,
D. Kannan,
. Nuaman,
P. Ashisha,
Akash Marathakam
Publication year - 2022
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2022/v34i3b35387
Subject(s) - favipiravir , pandemic , medicine , virology , regimen , virus , ebola virus , coronavirus , antiviral drug , covid-19 , antiviral therapy , intensive care medicine , disease , infectious disease (medical specialty) , chronic hepatitis
The emerging severe acute respiratory syndrome coronavirus 2 pandemic endangers patients and physicians all over the world. The potency of COVID-19 antiviral drugs is still a matter of debate. The growing understanding of COVID-19 virology and clinical manifestations is resulting in a larger pool of potential pharmacological targets. Favipiravir is included in the treatment regimen of many countries, including some regions of India, that have recently updated their treatment standards and is expected to be an effective treatment for SARS-CoV-2 infection, as it can be used to treat many different types of RNA virus infections such as Ebola, influenza, and the foot-and-mouth disease virus can be treated with this new nucleoside analogue. This review describes the status, mechanisms, pharmacokinetics, and antiviral effect of Favipiravir.